DK1487431T3 - Forebyggelse og/eller behandling af cardiovaskulær sygdom og/eller dermed associeret hjertefejl - Google Patents

Forebyggelse og/eller behandling af cardiovaskulær sygdom og/eller dermed associeret hjertefejl

Info

Publication number
DK1487431T3
DK1487431T3 DK03744567.3T DK03744567T DK1487431T3 DK 1487431 T3 DK1487431 T3 DK 1487431T3 DK 03744567 T DK03744567 T DK 03744567T DK 1487431 T3 DK1487431 T3 DK 1487431T3
Authority
DK
Denmark
Prior art keywords
patient
prevention
treatment
heart failure
cardiovascular disease
Prior art date
Application number
DK03744567.3T
Other languages
Danish (da)
English (en)
Inventor
Garth James Smith Cooper
John Richard Baker
Original Assignee
Philera New Zealand Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philera New Zealand Ltd filed Critical Philera New Zealand Ltd
Application granted granted Critical
Publication of DK1487431T3 publication Critical patent/DK1487431T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DK03744567.3T 2002-03-08 2003-03-10 Forebyggelse og/eller behandling af cardiovaskulær sygdom og/eller dermed associeret hjertefejl DK1487431T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NZ51772102 2002-03-08
NZ51772502 2002-03-11
US36438202P 2002-03-12 2002-03-12
PCT/NZ2003/000042 WO2003077901A1 (en) 2002-03-08 2003-03-10 Preventing and/or treating cardiovascular disease and/or associated heart failure

Publications (1)

Publication Number Publication Date
DK1487431T3 true DK1487431T3 (da) 2012-08-20

Family

ID=28046135

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03744567.3T DK1487431T3 (da) 2002-03-08 2003-03-10 Forebyggelse og/eller behandling af cardiovaskulær sygdom og/eller dermed associeret hjertefejl
DK11187394.9T DK2500018T3 (en) 2002-03-08 2003-03-10 Prevention and / or treatment of cardiovascular disease and / or associated heart failure

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11187394.9T DK2500018T3 (en) 2002-03-08 2003-03-10 Prevention and / or treatment of cardiovascular disease and / or associated heart failure

Country Status (10)

Country Link
US (4) US6951890B2 (cg-RX-API-DMAC10.html)
EP (2) EP2500018B1 (cg-RX-API-DMAC10.html)
JP (1) JP4860906B2 (cg-RX-API-DMAC10.html)
CN (1) CN1649577A (cg-RX-API-DMAC10.html)
AT (1) ATE555782T1 (cg-RX-API-DMAC10.html)
AU (1) AU2003225442B2 (cg-RX-API-DMAC10.html)
CA (1) CA2478997C (cg-RX-API-DMAC10.html)
DK (2) DK1487431T3 (cg-RX-API-DMAC10.html)
ES (1) ES2386782T3 (cg-RX-API-DMAC10.html)
WO (1) WO2003077901A1 (cg-RX-API-DMAC10.html)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018392A1 (en) 1998-09-25 2000-04-06 Glycox Corporation Limited Fructosamine oxidase: antagonists and inhibitors
EP1471931A4 (en) * 2001-08-24 2006-06-14 Maine Medical Ct Res Inst NON-TRADITIONAL EXPORT OF COPPER-DEPENDENT PRO-INFLAMMATORY CYTOKINES AND METHODS, COMPOSITIONS, AND KITS THEREOF
US20040038861A1 (en) * 2001-11-26 2004-02-26 Cooper Garth J. S. Methods and compositions for normalizing lipid levels in mammalian tissues
EP2500018B1 (en) 2002-03-08 2017-07-19 PhilERA New Zealand Limited Preventing and/or Treating Cardiovascular Disease and/or Associated Heart Failure
US6855340B2 (en) * 2002-05-24 2005-02-15 Regents Of The University Of Michigan Copper lowering treatment of inflammatory and fibrotic diseases
US20070248689A1 (en) * 2002-05-24 2007-10-25 Regents Of The University Of Michigan Copper lowering treatment of inflammatory and fibrotic diseases
US20040142393A1 (en) * 2002-08-01 2004-07-22 Cooper Garth James Smith Methods of use of compounds with preptin function
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20060100278A1 (en) * 2002-08-20 2006-05-11 Cooper Garth J S Dosage forms and related therapies
US20050096256A1 (en) 2003-07-01 2005-05-05 President And Fellows Of Harvard College Compositions for manipulating the lifespan and stress response of cells and organisms
CA2550505A1 (en) * 2003-12-19 2005-06-30 Protemix Corporation Limited Copper antagonist compounds
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
EP1708689A2 (en) 2003-12-29 2006-10-11 The President and Fellows of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US7563460B2 (en) * 2004-02-26 2009-07-21 Med Five, Inc. Enteric coated oral pharmaceutical to erode kidney stones
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
EP1778618B1 (en) 2004-07-19 2013-12-25 PhilERA New Zealand Limited Synthesis of triethylenetetramines
HU227588B1 (hu) * 2004-12-03 2011-09-28 Sinnex Mueszaki Fejlesztoe Es Tanacsado Kft Többszörösen telítetlen zsírsavak észtereit tartalmazó vírusellenes és immunstimuláns gyógyászati készítmény
WO2006104402A1 (en) * 2005-03-26 2006-10-05 Protemix Corporation Limited Copper antagonist compositions
WO2006104398A1 (en) * 2005-03-26 2006-10-05 Protemix Corporation Limited Copper antagonist compositions
EP1874285B1 (en) * 2005-04-07 2009-10-07 Astrum Therapeutics Pty, Ltd. Complementary compositions to reduce blood glucose levels and treat diabetes
AU2006240568A1 (en) * 2005-04-25 2006-11-02 Philera New Zealand Limited Copper regulation evaluation and therapy
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
EP1948160A4 (en) * 2005-11-09 2013-07-10 Protemix Corp Ltd TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS
JP2009523175A (ja) * 2006-01-10 2009-06-18 パイペックス，インコーポレイテッド 目標とされる安定な銅状態を達成及び維持して銅関連中枢神経系疾患を予防及び治療するための医薬組成物及び方法
KR100821649B1 (ko) 2006-01-24 2008-04-11 서울시립대학교 산학협력단 클리오퀴놀을 유효성분으로 포함하는 ＨＩＦ-1α 활성제
CN101437503A (zh) * 2006-02-21 2009-05-20 阿斯特鲁姆医疗有限公司 用于降低血糖水平和治疗糖尿病的组合物
WO2007116243A2 (en) * 2006-04-10 2007-10-18 Mintails Limited Method for treating fibromyalgia and related conditions
US20090270420A1 (en) * 2006-06-01 2009-10-29 Sobel Burton E Methods for inhibiting cardiac pai-1
KR100816798B1 (ko) * 2006-09-08 2008-03-25 (주)팜스웰 의약용 트리에틸렌테트라민 이염산염의 제조방법
CN101702884A (zh) * 2007-03-09 2010-05-05 西姆科皮亚公司 用于治疗高血糖症及相关病症的脂肪酸氧化抑制剂
US20100311092A1 (en) * 2007-11-30 2010-12-09 Kurland Irwin J Metabolic fuel switching biomarker
WO2010020959A1 (en) * 2008-08-21 2010-02-25 University Of Cape Town Resveratrol-containing composition for treating heart failure
US20100234906A1 (en) * 2009-03-16 2010-09-16 Pacesetter, Inc. System and method for controlling rate-adaptive pacing based on a cardiac force-frequency relation detected by an implantable medical device
JP5896375B2 (ja) 2011-09-09 2016-03-30 池田食研株式会社 改変型グルコース脱水素酵素遺伝子
WO2014145705A2 (en) 2013-03-15 2014-09-18 Battelle Memorial Institute Progression analytics system
WO2014152207A1 (en) 2013-03-15 2014-09-25 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
CZ307108B6 (cs) * 2013-09-06 2018-01-17 Vysoké Učení Technické V Brně Multifunkční poloprovozní jednotka pro snižování polutantů z odpadního plynu
EP2845640B1 (en) 2013-09-06 2018-10-24 Vysoké Ucení Technické V Brne Multifunction operation unit for reducing pollutant concentration in a waste gas
JP2018505407A (ja) 2015-01-07 2018-02-22 ノッティンガム ユニバーシティ ホスピタルズ エヌエイチエス トラストＮｏｔｔｉｎｇｈａｍ Ｕｎｉｖｅｒｓｉｔｙ Ｈｏｓｐｉｔａｌｓ Ｎｈｓ Ｔｒｕｓｔ 検査方法、原子種の使用方法、検査装置、及び、テストキット
WO2017049529A1 (en) * 2015-09-24 2017-03-30 Innolife Co., Ltd. A pharmaceutical composition comprising a copper chelating tetramine and the use thereof
WO2018005990A2 (en) * 2016-07-01 2018-01-04 Marshall University Research Corporation Compositions and methods for treating uremic cardiomyopathy
CN107811997A (zh) * 2017-11-10 2018-03-20 大连医科大学附属第医院 蛋白酶体抑制剂白藜芦醇在预防和治疗心血管疾病中的应用
TWI902661B (zh) 2018-05-04 2025-11-01 法商奧法蘭股份公司 三伸乙基四胺四鹽酸鹽之結晶型及其醫藥用途
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
EP3947433A4 (en) * 2019-04-02 2022-11-23 The Regents of The University of Michigan USE OF SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR LEVELS IN THE MANAGEMENT OF PATIENTS WITH CARDIOVASCULAR DISEASES
CN114867474A (zh) * 2019-06-17 2022-08-05 菲勒拉新西兰有限责任公司 中枢神经系统病症的联合治疗
CN112138024A (zh) 2019-06-26 2020-12-29 里弗斯Pah有限责任公司 治疗严重形式的肺动脉高压的方法
CN110464717B (zh) * 2019-09-23 2022-02-18 张建国 一种2,4-二羟基苯甲酸在制备降低血糖的药物的应用
GB2612210B (en) * 2020-06-24 2025-08-27 Reverspah Llc Pharmaceutical composition comprising a tetrathiomolybdate salt and a diethylcarbamazine
CN115998955B (zh) * 2022-12-09 2024-12-20 首都医科大学附属北京安贞医院 一种静脉桥的醛铬复合交联方法
KR102878403B1 (ko) * 2023-01-25 2025-10-28 김성국 동맥경화 치료용 킬레이션 약학 조성물 및 체외 역박동기를 이용한 동맥경화 치료용 킬레이션 약학 조성물의 투여방법

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3791988A (en) 1972-03-23 1974-02-12 Hoffmann La Roche Diagnostic test for glucose
PL105793B1 (pl) 1977-11-24 1979-10-31 Sposob otrzymywania soli kwasow dwukarboksylowych i poliamin
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4323558A (en) 1979-09-10 1982-04-06 Nelson Research & Development Co. Topical trien containing pharmaceutical compositions and methods of use
US4371374A (en) 1980-11-17 1983-02-01 The Rockefeller University Monitoring metabolic control in diabetic patients by measuring glycosylated amino acids and peptides in urine
JPS57144215A (en) 1981-03-02 1982-09-06 Nippon Nousan Kogyo Kk Composition for improving lipometabolism
DE3217071A1 (de) 1982-05-06 1983-11-10 Rüdiger Dr. 6365 Rosbach Gröning Arzneimittel fuer die perorale applikation mit verbesserter biologischer verfuegbarkeit der wirkstoffe
US4758583A (en) 1984-03-19 1988-07-19 The Rockefeller University Method and agents for inhibiting protein aging
US4665192A (en) 1984-03-19 1987-05-12 The Rockefeller University 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole
US5852009A (en) 1984-03-19 1998-12-22 The Rockefeller University Compositions, including pharmaceutical compositions, for inhibiting the advanced glycosylation of proteins, and therapeutic methods based thereon
EP0302065B1 (en) 1986-03-21 1994-08-10 Eurasiam Laboratories, Inc. Pharmaceutical compositions
CH666814A5 (it) 1986-07-24 1988-08-31 Inpharzam Int Sa Composizione farmaceutica idrosolubile contenente n-acetil-cisteina.
CH667590A5 (it) 1986-07-24 1988-10-31 Inpharzam Int Sa Composizione farmaceutica effervescente idrosolubile contenente n-acetil-cisteina. .
US4866090A (en) 1988-01-07 1989-09-12 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
EP0331014A3 (de) 1988-03-02 1991-10-23 THERA - Patent Verwaltungs-GmbH Verwendung von ACE-Inhibitoren für die Diabetesprophylaxe
JPH01294631A (ja) 1988-05-19 1989-11-28 Sanwa Kagaku Kenkyusho Co Ltd 糖尿性疾患治療予防剤及び飲食、し好物
US5077313A (en) 1988-11-25 1991-12-31 Gert Lubec Process for inhibiting pathological collagen cross-linking in diabetes patients
CA2026686A1 (en) 1989-10-30 1991-05-01 Werner Tschollar Method for preventing onset of type ii diabetes employing an ace inhibitor
US5447728A (en) 1992-06-15 1995-09-05 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
AU667069B2 (en) 1991-12-06 1996-03-07 North Shore University Hospital Research Corporation Method of reducing medical device related infections
US5246970A (en) 1991-12-16 1993-09-21 Washington University Method of inhibiting nitric oxide formation
JP3157622B2 (ja) 1992-06-05 2001-04-16 株式会社ミツカングループ本社 フルクトシルアミンデグリカーゼ、その製造法及び該酵素を用いたアマドリ化合物の定量方法
JPH06298738A (ja) * 1993-04-15 1994-10-25 Yamanouchi Pharmaceut Co Ltd ５−アミノピラゾール誘導体
JPH07118148A (ja) 1993-10-26 1995-05-09 Tsumura & Co 肝癌予防剤
US5420120A (en) 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
AU1447095A (en) 1993-12-30 1995-07-17 Arcturus Pharmaceutical Corporation Methods for the treatment of the central nervous system or eye involving pathogenic oxidation pathways
US5854271A (en) 1994-05-02 1998-12-29 Cytos Pharmaceuticals, L.L.C. Effective method for the amelioration and prevention of tissue and cellular damage
AU4134996A (en) 1994-10-25 1996-05-15 Washington University Method of inhibiting nitric oxide formation
AU716005B2 (en) 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
JP3988838B2 (ja) * 1996-05-29 2007-10-10 日本製粉株式会社 化粧料
US5906996A (en) 1996-08-21 1999-05-25 Murphy; Michael A. Tetramine treatment of neurological disorders
EP1007048A4 (en) 1997-03-11 2004-09-22 Gen Hospital Corp IDENTIFICATION OF MEANS FOR TREATING ALZHEIMERISCHEN DISEASE
JPH10324629A (ja) * 1997-03-28 1998-12-08 Otsuka Pharmaceut Co Ltd Ａｇｅ生成阻害組成物
US5811446A (en) 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US20030013772A1 (en) 2000-02-23 2003-01-16 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US20050085555A1 (en) 1997-08-21 2005-04-21 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US6576672B1 (en) 1998-08-21 2003-06-10 Michael A. Murphy Polyamine treatment of neurological disorders
US5980914A (en) 1997-08-22 1999-11-09 P.N. Gerolymatos S.A. Clioquinol for the treatment of Parkinson's disease
US6821954B2 (en) 1997-09-18 2004-11-23 Auckland Uniservices Limited Compounds and uses thereof in treating bone disorders
US5972985A (en) 1997-11-03 1999-10-26 Cytos Pharmaceuticals, Llc Histidine containing nutriceutical compositions
AU754681B2 (en) 1998-02-04 2002-11-21 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
US6323218B1 (en) 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6147070A (en) * 1998-06-05 2000-11-14 Facchini; Francesco Methods and compositions for controlling iron stores to treat and cure disease states
EP1234585A3 (en) 1998-09-04 2004-01-21 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
WO2000018392A1 (en) 1998-09-25 2000-04-06 Glycox Corporation Limited Fructosamine oxidase: antagonists and inhibitors
CN1320160A (zh) 1998-09-25 2001-10-31 格利科克斯有限公司 果糖胺氧化酶测定的方法和材料
JP2000204037A (ja) 1999-01-12 2000-07-25 Tsumura & Co 筋萎縮性側索硬化症治療薬
US6309380B1 (en) 1999-01-27 2001-10-30 Marian L. Larson Drug delivery via conformal film
EP1185558A4 (en) 1999-06-18 2006-02-15 Protemix Discovery Ltd PEPTIDES WITH PREPTID FUNCTIONALITY
US20030050434A1 (en) 1999-06-18 2003-03-13 Cooper Garth J.S. Peptide
US20030166561A1 (en) 1999-06-18 2003-09-04 Cooper Garth J. S. Peptide
DE60129427T3 (de) 2000-05-11 2014-07-24 The Procter & Gamble Company Hochkonzentrierte wäscheweichspülerzusammensetzungen und diese enthaltende mittel
EP1370254B1 (en) 2000-12-01 2008-01-16 Radical Vision Therapeutics Inc. Copper chelators for treating ocular inflammation
US7754765B2 (en) 2000-12-01 2010-07-13 Radical Vision Therapeutics Inc Copper chelators for treating ocular inflammation
EP1373893A2 (en) 2001-03-30 2004-01-02 Protemix Corporation Limited Phosphoprotein target for insulin and its antagonists
WO2003002732A1 (en) 2001-06-27 2003-01-09 Biovitrum Ab Citrate lyase poly peptides
EP1417055A4 (en) 2001-07-19 2007-09-26 Dmi Biosciences Inc USE OF COPPER CHELATORS TO PREVENT THE INACTIVATION OF PROTEIN C
EP1461068A4 (en) 2001-11-26 2006-03-29 Protemix Corp Ltd METHOD AND COMPOSITIONS FOR NORMALIZING LIPID MIRRORS IN MIRACLE TISSUE
US20040038861A1 (en) 2001-11-26 2004-02-26 Cooper Garth J. S. Methods and compositions for normalizing lipid levels in mammalian tissues
US7144706B2 (en) 2002-01-03 2006-12-05 Duke University Methods of modulating localization and physiological function of IP3 receptors
JP2005535561A (ja) 2002-01-18 2005-11-24 プロテミックス コーポレイション リミティド アディポネクチンのグリコアイソフォームとその使用
EP1465982A4 (en) 2002-01-25 2006-06-07 Gamida Cell Ltd PROCESS FOR EXPANSION OF STEM AND PRESERVATIVE CELLS AND EXPANDED CELL POPULATIONS THEREWITH OBTAINED
CN1688299A (zh) 2002-01-29 2005-10-26 普罗特米克斯公司 抑制细胞毒性蛋白构象异构体
AU2003225440A1 (en) 2002-03-01 2003-09-16 Protemix Discovery Limited Falp proteins
EP2500018B1 (en) 2002-03-08 2017-07-19 PhilERA New Zealand Limited Preventing and/or Treating Cardiovascular Disease and/or Associated Heart Failure
AU2003222513A1 (en) * 2002-03-08 2003-09-22 Protemix Corporation Limited Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
EP1494658B1 (en) 2002-04-03 2006-01-04 Puleva Biotech, S.A. Natural phenolic products and derivatives thereof for protection against neurodegenerative diseases
WO2003093311A1 (en) 2002-04-29 2003-11-13 Protemix Corporation Limited Proteins with deglycating activities and methods of using same
US6855340B2 (en) 2002-05-24 2005-02-15 Regents Of The University Of Michigan Copper lowering treatment of inflammatory and fibrotic diseases
JP2003343552A (ja) * 2002-05-27 2003-12-03 Koyo Seiko Co Ltd 円錐ころ軸受
GEP20074270B (en) 2002-07-23 2007-12-25 Univ Michigan Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
US7189865B2 (en) 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
WO2004012760A1 (en) 2002-08-01 2004-02-12 Auckland Uniservices Limited Preptin methods of use
EP1534321A1 (en) 2002-08-01 2005-06-01 Protemix Corporation Limited Methods of use of compounds with preptin function
US20040142393A1 (en) 2002-08-01 2004-07-22 Cooper Garth James Smith Methods of use of compounds with preptin function
AU2003214725A1 (en) 2002-08-20 2004-03-11 Protemix Corporation Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
US20060100278A1 (en) 2002-08-20 2006-05-11 Cooper Garth J S Dosage forms and related therapies
AU2003285686A1 (en) 2002-12-23 2004-07-14 Protemix Corporation Limited Glycoisoforms of adiponectin and uses thereof
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
EP1606292A2 (en) 2003-03-21 2005-12-21 Palumed SA Nitrogeneous polycyclic derivatives useful as chelators of metal ions and their applications
EP1617844A4 (en) 2003-04-03 2009-07-22 Prana Biotechnology Ltd TREATMENT OF NEUROLOGICAL DISEASES
AU2004238285A1 (en) 2003-05-07 2004-11-25 Dmi Biosciences, Inc Oral care methods and products
US7176239B2 (en) 2003-07-11 2007-02-13 Suming Wang Methods and compositions for treatment of Ataxia-telangeictasia
WO2005040205A1 (en) 2003-10-28 2005-05-06 Protemix Discovery Limited Peptides with anti-obesity activity and other related uses
CA2550505A1 (en) 2003-12-19 2005-06-30 Protemix Corporation Limited Copper antagonist compounds
EP1778618B1 (en) 2004-07-19 2013-12-25 PhilERA New Zealand Limited Synthesis of triethylenetetramines
WO2006068516A1 (en) 2004-12-20 2006-06-29 Protemix Corporation Limited Implantable medical devices coated with or containing copper chelating compounds

Also Published As

Publication number Publication date
AU2003225442A1 (en) 2003-09-29
US20110212188A1 (en) 2011-09-01
US8563538B2 (en) 2013-10-22
JP2005533003A (ja) 2005-11-04
CA2478997C (en) 2013-12-17
CA2478997A1 (en) 2003-09-25
EP2500018A1 (en) 2012-09-19
US20060009534A1 (en) 2006-01-12
US20140113969A1 (en) 2014-04-24
AU2003225442B2 (en) 2010-02-04
US8987244B2 (en) 2015-03-24
WO2003077901A1 (en) 2003-09-25
US6951890B2 (en) 2005-10-04
US20030203973A1 (en) 2003-10-30
EP2500018B1 (en) 2017-07-19
DK2500018T3 (en) 2017-10-02
JP4860906B2 (ja) 2012-01-25
EP1487431A4 (en) 2006-10-25
HK1071313A1 (en) 2005-07-15
EP1487431B1 (en) 2012-05-02
CN1649577A (zh) 2005-08-03
US8034799B2 (en) 2011-10-11
ES2386782T3 (es) 2012-08-30
EP1487431A1 (en) 2004-12-22
ATE555782T1 (de) 2012-05-15

Similar Documents

Publication Publication Date Title
EP1487431A4 (en) PREVENTING AND / OR TREATING CARDIOVASCULAR DISEASE AND / OR RELATED CARDIAC INSUFFICIENCY
PT1267897E (pt) Tratamento da insufuciencia cardiaca congestiva com sangue autologo previamente tratado
CO5611156A2 (es) Metodos de tratamiento de enfermedad vascular
ATE355852T1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
WO2001049236A3 (en) Method and system for treating cardiac arrest
WO2005030291A3 (en) Method and apparatus for treatment of thrombosed hemodialysis access grafts
ATE514389T1 (de) Ablationskatheter
DE69738184D1 (de) Lösung und verfahren zur wiederbelebung und heilung von ischämisch beschädigtem gewebe
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
NO951066L (no) Transkutan in vivo aktivering av fotosensitive midler i blod
NO20076121L (no) Behandlinger for kardiovaskulaer sykdom
BRPI0607460A2 (pt) braquiterapia periférica de órgãos protrusos moldáveis
DE60137635D1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
AU2003214725A1 (en) Preventing and/or treating cardiovascular disease and/or associated heart failure
EP1588736A3 (en) Microperfusive electrical stimulation
ATE489963T1 (de) Chaperonin-10-immunosuppression
WO2003061534A3 (en) Inflatable blanket for use in cardiac surgery
EA199900724A1 (ru) Способы лечения, профилактики и защиты кровеносных сосудов от повреждений (варианты), способы лечения и профилактики различных видов гипертензии, атеросклероза (варианты)
ATE419037T1 (de) Verwendung eines mittel zur therapie der herzhypertrophie
UA85548C2 (ru) Применение водного экстракта листьев красного винограда для предупреждения перехода от клинически незначительных ранних стадий хронической венозной недостаточности к i, ii или iii стадии
DE60122680D1 (de) Kannulationsanordnung
WO2002062204A3 (en) Methods for diagnosing and treating heart disease
WO2006007710A3 (en) Acute inflammatory condition treatment
WO2002085376A3 (en) A method for decreasing superoxide anion production and for the treatment of diseases associated with oxidative stress
RU2002115574A (ru) Способ лечения эпидидимоорхита